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Infection/Inflammation
Risk Factors for Acute Prostatitis after Transrectal Biopsy of the 
Prostate
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Purpose: To investigate the incidence, clinical features, pathogenic bacteria, and risk 
factors associated with acute prostatitis after transrectal prostate biopsy.
Materials and Methods: We retrospectively reviewed the medical records of 923 trans-
rectal ultrasound-guided needle biopsies of the prostate in 878 patients performed at 
our institution from June 2004 to May 2009. The indications for biopsy were generally 
serum prostate-specific antigen (PSA) elevation, abnormal findings on a digital rectal 
examination, or both. All biopsies were performed with the patient hospitalized except 
for 10 patients who refused to be hospitalized, and ciprofloxacin was administered as 
an antibiotic prophylaxis. The incidence, clinical features, pathogenic bacteria, and po-
tential risk factors associated with acute prostatitis after prostate biopsy were evaluated.
Results: Acute prostatitis developed in 18 (2.0%) cases after prostate biopsy. Among 
them, 9 (1.0%) had bacteremia and 2 (0.2%) showed clinical features of sepsis. Of the 
total 50 urine or blood specimens sent for culture study, 27 (54.0%) specimens showed 
positive cultures, including E. coli in 25. Among the 27 culture-positive specimens, 26 
(96.3%) were resistant to ciprofloxacin. Among the potential risk factors for acute pros-
tatitis after prostate biopsy, biopsy performed as an outpatient procedure without a 
cleansing enema (p=0.001) and past history of cerebrovascular accident (p=0.048) were 
statistically significant.
Conclusions: Fluoroquinolone is effective as an antibiotic prophylaxis for transrectal 
prostate biopsy in most cases. The incidence of acute prostatitis after transrectal pros-
tate biopsy was 2.0%, and almost all cases were caused by fluoroquinolone-resistant 
E. coli. A cleansing enema is recommended before transrectal prostate biopsy.
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INTRODUCTION
Transrectal ultrasound-guided needle biopsy of the pros-
tate is generally accepted as the standard diagnostic proce-
dure for detecting prostate cancer [1-4]. Although trans-
rectal ultrasound-guided prostate biopsy is generally con-
sidered to be a safe procedure, complications are occasion-
ally encountered. These include minor complications such 
as hematuria, hemospermia, and rectal bleeding as well as 
clinically significant, major complications such as acute 
prostatitis and urosepsis, which may be fatal [5-8].
　Antibiotic prophylaxis before transrectal prostate biop-
sy is generally accepted to reduce the infection-related 
complications. Fluoroquinolones, which are known to be 
delivered at high concentrations in the prostate, are con-
sidered to be effective in lowering the incidence of infective 
complications [9-12]. However, there are recent reports of 
the development of fluoroquinolone-resistant infections 
after transrectal prostate biopsy [13-16].
　The number of prostate biopsies is bound to pro-
gressively increase with the advent of prostate-specific an-
tigen (PSA) screening and increasing awareness of pros-
tate cancer. Therefore, it becomes essential to have a clear 
understanding of the morbidity of transrectal prostate bi-Korean J Urol 2010;51:426-430
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TABLE 1. Susceptibility of ciprofloxacin-resistant E. coli to 
antibiotics in 24 urine and blood culture specimens
Antibiotics % susceptible
Trimethoprim/sulfamethoxazole   67
Ampicillin   38
Amoxicillin/clavulanic acid   86
Piperacillin   64
Piperacillin/tazobactam 100
Aztreonam 100
Imipenem 100
Tetracycline   50
Nitrofurantoin 100
Ceftazidime 100
Cefepime 100
Cefazolin   92
Cefoxitin   88
Cefotaxime 100
Ceftriaxone 100
Amikacin 100
Gentamicin   96
Netilmicin 100
Tobramycin 100
TABLE 2. Annual rates of acute prostatitis that developed after 
prostate biopsy
Year
No. of prostate 
biopsies
No. of cases with 
acute prostatitis (%)
p-value
2004
2005
2006
2007
2008
2009
  77
124
155
218
227
122
2 (2.6)
1 (0.8)
4 (2.6)
5 (2.3)
4 (1.8)
2 (1.6)
0.904
Total 923 18 (2.0)
opsy to allow for more appropriate patient counseling and 
management.
　In this study, we investigated the incidence, clinical fea-
tures, pathogenic bacteria, and risk factors associated with 
acute prostatitis after transrectal prostate biopsy.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 923 
prostate biopsies, including 77 repeated biopsies, per-
formed in 878 patients at our institution from June 2004 
to May 2009. The indications for prostate biopsy were se-
rum PSA elevation or abnormal findings on a digital rectal 
examination or transrectal ultrasonography. All prostate 
biopsies were performed transrectally under ultrasound 
guidance by a radiologist. An automatic biopsy gun with 
an 18-gauge needle was used to obtain the biopsy specimens. 
Either 10- or 12-core biopsies were sampled depending on 
the time period during which the biopsy was performed. 
Ten-core biopsies were performed from June 2004 to April 
2008, and 12-core biopsies were performed since May 2008. 
As a rule, acetylsalicylic acid or oral anticoagulant agents 
were stopped 7 days before prostate biopsy with the appro-
val of the prescribing physician. Urine samples were ob-
tained for urinalysis before prostate biopsy in all cases ex-
cept 5 and for urine culture in all cases except 10.
　All prostate biopsies were performed with the patient 
hospitalized except for 10 patients who refused to be 
hospitalized. In patients who were hospitalized, 200 mg ci-
profloxacin was injected intravenously before and after the 
biopsy. All hospitalized patients received a cleansing ene-
ma before biopsy. They were discharged from the hospital 
on the following morning after the biopsy and received 250 
mg ciprofloxacin orally twice daily for 7 days. Patients who 
underwent the biopsy on an outpatient basis did not receive 
a cleansing enema or parenteral injections of ciprofloxacin. 
These patients received 250 mg ciprofloxacin orally twice 
daily for 7 days, beginning on the morning before biopsy. 　
If symptoms of acute prostatitis, such as fever, chills, and 
voiding difficulty, developed after prostate biopsy, the pa-
tient was readmitted for treatment including intravenous 
antibiotics.
　The incidence, clinical features, and pathogenic bacteria 
of acute prostatitis after prostate biopsy were investigated. 
Variables such as the patient’s age, past medical history, 
prostate volume, biopsy core numbers, number of biopsy 
sessions, cleansing enema, and urinalysis and urine cul-
ture findings before biopsy were also assessed.
　Statistical analysis was performed by using the chi- 
square test or independent t-test with SPSS version 13.0 
(SPSS Inc., Chicago, USA). Values of p＜0.05 were consid-
ered to be statistically significant in all of the analyses.
RESULTS
Of the 923 prostate biopsy cases, acute prostatitis devel-
oped in 18 (2.0%) cases after prostate biopsy. Among these 
18 cases, 9 (1.0%) had bacteremia as confirmed by positive 
blood culture, and 2 (0.2%) showed clinical features of 
sepsis. The patients developed infective symptoms a me-
dian of 1 day (mean, 2.8 days; range, 1-25 days) after pros-
tate biopsy.
　Of the 18 cases with acute prostatitis, 13 (72.2%) cases 
had positive urine and/or blood cultures, including E. coli 
in 11, Klebsiella pneumoniae in 1, and Citrobacter freundii 
in 1. Of the total 50 urine or blood specimens sent for culture 
study, 27 (54.0%) specimens showed positive cultures, in-
cluding E. coli in 25, Klebsiella pneumoniae in 1, and Citro-
bacter freundii in 1. Among the 27 culture-positive speci-
mens, 26 (96.3%) yielded ciprofloxacin-resistant patho-
gens, including E. coli in 24, Klebsiella pneumoniae in 1, 
and Citrobacter freundii in 1. However, these pathogens 
were sensitive to cephalosporins and aminoglycosides 
(Table 1).
　When stratified by year, there was no statistically sig-
nificant difference in the annual rates of acute prostatitis 
that developed after prostate biopsy (p=0.904) (Table 2).Korean J Urol 2010;51:426-430
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TABLE 3. Patient’s age and prostate volume in relation to acute prostatitis
Total With acute prostatitis Without acute prostatitis p-value
Mean age±SD (years)
Mean prostate volume±SD (cc)
65.4±11.1
50.2±29.1
59.3±13.0
44.7±20.1
65.5±11.0
50.3±29.3
0.063
0.261
TABLE 4. Potential risk factors and rates of acute prostatitis 
after prostate biopsy
Risk factors
No. of 
prostate 
biopsies
No. of cases 
with acute 
prostatitis (%)
p-value
Diabetes mellitus 0.095
　Yes 131   5 (3.8)
　No 792 13 (1.6)
Hypertension 0.840
　Yes 338   7 (2.1)
　No 585 11 (1.9)
Cerebrovascular accident 0.048
　Yes   54   3 (5.6)
　No 869 15 (1.7)
Pyuria before biopsy 0.941
　Yes   57   1 (1.8)
　No 861 14 (1.6)
Urine culture before biopsy 0.771
　Positive   46   1 (2.2)
　Negative 867 14 (1.6)
No. of biopsy core 0.709
　10 652 12 (1.8)
　12 271   6 (2.2)
No. of biopsy session 0.645
　1st 846 18 (2.1)
　2nd   63 0 (0)
　3rd   12 0 (0)
　4th     2 0 (0)
Cleansing enema 0.001
　Yes (biopsy in IPD) 913 15 (1.6)
　No (biopsy in OPD)   10     3 (30.0)
IPD: inpatient department, OPD: outpatient department
　The mean age of the patients who underwent prostate 
biopsy was 65.4 years (range, 20-95 years). The mean ages 
of the patients who developed acute prostatitis and of those 
who did not were 59.3±13.0 years and 65.5±11.0 years, re-
spectively, which showed no statistically significant differ-
ence (p=0.063) (Table 3).
　The mean prostate volume of the patients who under-
went prostate biopsy was 50.2 cc (range, 12.2-383.3 cc). The 
mean prostate volumes of the patients who developed acute 
prostatitis and of those who did not were 44.7±20.1 cc and 
50.3±29.3 cc, respectively, which showed no statistically 
significant difference (p=0.261) (Table 3).
　Among the other potential risk factors for acute prostati-
tis after prostate biopsy, biopsy performed as an outpatient 
procedure without a cleansing enema (p=0.001) and past 
history of cerebrovascular accident (p=0.048) were statisti-
cally significant (Table 4).
DISCUSSION
Although a few studies have demonstrated that antibiotic 
prophylaxis may not be required for transrectal prostate 
biopsy [17], antibiotic prophylaxis before transrectal pros-
tate biopsy is generally accepted to decrease the rate of in-
fective complications [9-12]. However, there is much varia-
bility in the type, dosage, and duration of antibiotic prophy-
laxis [18,19].
　Fluoroquinolones are the most frequently used anti-
biotics for prophylaxis before transrectal prostate biopsy 
because of their broad spectrum of action, which is ad-
equate for common urinary and colorectal flora; their high 
concentration within the prostatic tissue; and the ease of 
oral administration [20]. Numerous studies have demon-
strated a decrease in infective complications with fluo-
roquinolone use to rates of less than 1% to 4% [9,10,12-14, 
21]. In our study, the rate of acute prostatitis was 2.0%, 
which is consistent with the previously reported rates. This 
means that fluoroquinolone is effective as an antibiotic pro-
phylaxis for transrectal prostate biopsy in most cases.
　However, recent reports have shown that fluoroquinolone- 
resistant infections following transrectal prostate biopsy 
are emerging [9,10,13-16,21]. Shigehara et al reported that 
all of the urine cultures of patients with acute prostatitis 
that developed after transrectal prostate biopsy yielded 
levofloxacin-resistant E. coli [9]. Feliciano et al showed 
that 61% of the patients with infective complications after 
transrectal prostate biopsy had positive urine and/or blood 
cultures. Of the positive cultures, those from 89% of pa-
tients yielded E. coli and 90% were fluoroquinolone-resis-
tant. The incidence of infective complications and fluo-
roquinolone-resistant infections in 2006 were 3 times and 
3.3 to 4.3 times higher than in 2004 and 2005, respectively 
[13]. Özden et al reported that 61% of the patients with 
acute prostatitis after transrectal prostate biopsy had pos-
itive cultures, with E. coli being the most common pathogen 
(82%). Among the patients infected with E. coli, 93% 
showed fluoroquinolone resistance and 43% harbored ex-
tended-spectrum β-lactamase-producing E. coli [16]. In 
our study, 72.2% of cases with acute prostatitis after trans-
rectal prostate biopsy had positive urine and/or blood 
cultures. Of the positive cultures, 96.3% were resistant to 
ciprofloxacin. However, in contradiction to the findings by 
Feliciano et al, there was no significant difference in the 
annual rates of acute prostatitis after prostate biopsy [13].
　Özden et al suggested that the increasing fluoroquinolone 
resistance might be due to the previous wide use of these 
drugs [16]. Shigehara et al considered that the previous use 
of levofloxacin might cause bacterial selection in the rec-Korean J Urol 2010;51:426-430
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tum, and levofloxacin-resistant E. coli might then appear 
in the rectum for a certain period [9]. In their reports, acute 
prostatitis developed more frequently after repeat biopsy 
than after the first biopsy [9,16]. However, in our study, the 
rate of acute prostatitis did not differ according to the num-
ber of biopsy sessions, and all cases of acute prostatitis oc-
curred after the first biopsy.
　Because our results showed that ciprofloxacin-resistant 
pathogens were sensitive to cephalosporins and amino-
glycosides, empirical treatment with cephalosporins or 
aminoglycosides is recommended in patients with acute 
prostatitis that develops after transrectal prostate biopsy 
until culture-specific therapy can be implemented.
　The impact of cleansing enemas before transrectal pros-
tate biopsy on the infective complications is still contro-
versial. Whereas some studies have shown that a cleansing 
enema is not required or recommended before biopsy 
[22,23], others have suggested that a cleansing enema be-
fore biopsy may decrease bacteremia and bacteriuria after 
prostate biopsy [24,25]. A cleansing enema has the advant-
age of producing a superior acoustic window for prostate 
imaging by decreasing the amount of feces in the rectum. 
Furthermore, a cleansing enema and an empty rectal vault 
may reduce bacterial seeding of the prostate [26].
　In our series of 923 prostate biopsy cases, all patients ex-
cept 10 (1.1%) received a cleansing enema. Acute prostati-
tis developed more frequently in cases without a cleansing 
enema than in those with a cleansing enema before biopsy, 
and this difference was statistically significant. Because 
only 1.1% of our cases did not receive a cleansing enema, 
however, a large, prospective randomized study will be 
needed to clarify the impact of a cleansing enema on in-
fective complications.
　In our study, biopsy performed as an outpatient proce-
dure without a cleansing enema and past history of cere-
brovascular accident were statistically significant risk fac-
tors for acute prostatitis after transrectal prostate biopsy. 
Pyuria and positive urine culture before biopsy were not 
significant risk factors, which is consistent with the find-
ings of Ecke et al that positive microbiology in urine before 
prostate biopsy is not a risk factor for a higher infection rate 
[27]. Chiang et al suggested that patients with a larger 
prostate (＞45 ml) had a significantly higher risk of devel-
oping acute prostatitis and acute urinary retention after 
prostate biopsy than did those with a smaller prostate 
(＜45 ml) [28]. However, in our study, prostate volume was 
not a significant risk factor for acute prostatitis after pros-
tate biopsy.
　In our study, patient’s age, diabetes mellitus, hyper-
tension, and number of biopsy cores were not significant 
risk factors for acute prostatitis after prostate biopsy, 
which is consistent with the results of a study by Chiang 
et al [28]. Past history of cerebrovascular accident was a 
statistically significant risk factor for acute prostatitis af-
ter prostate biopsy in our study, but not in the report by 
Chiang et al [28]. The possible explanation is that the pa-
tients with a history of cerebrovascular accident may have 
altered bowel function and constipation [29,30], which may 
result in a change in the bacterial flora in the rectum. They 
also could have consumed fluoroquinolones before prostate 
biopsy. These combined might lead to the appearance of flu-
oroquinolone-resistant pathogens in the rectum and an in-
crease in infective complications after transrectal prostate 
biopsy.
　A limitation of our study is that it was retrospective in 
nature, and the sample size of the groups was limited be-
cause of the low incidence of acute prostatitis after trans-
rectal prostate biopsy. All patients except 10 (1.1%) were 
hospitalized and received a cleansing enema before trans-
rectal prostate biopsy. Further prospective studies will be 
necessary to confirm the impact on infective complications 
of a cleansing enema before transrectal prostate biopsy.
CONCLUSIONS
Fluoroquinolone is effective as an antibiotic prophylaxis 
for transrectal prostate biopsy in most cases. The incidence 
of acute prostatitis after transrectal prostate biopsy was 
2.0%, and almost all cases were caused by fluoroquinolone- 
resistant E. coli. A cleansing enema is recommended before 
transrectal prostate biopsy. Empirical treatment with 
cephalosporins or aminoglycosides should be initiated for 
patients with acute prostatitis after transrectal prostate 
biopsy until culture-specific therapy can be implemented.
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